Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Prostate02 sub-study MK-2400-01A in metastatic castration-resistant prostate cancer
MOH_2025-06-15_014127Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ifinatamab deruxtecan in prostate cancer (PCa) (4 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability, PSA response rate and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2025-06-15_014127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-15_014127.